Roth Capital initiated coverage on Biofrontera with a new price target
$BFRI
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $11.00 | Buy | Benchmark |
| 11/24/2021 | $20.00 | Buy | Roth Capital |
Biofrontera Inc. has signed an agreement to acquire all US assets related to Ameluz® and RhodoLED® including New Drug Application (NDA) and associated patents from Germany-based Biofrontera AG.Under their new agreement, the effective royalty rate paid by Biofrontera Inc. will be reduced to 12% (and 15% above revenue of $65 million) of net sales from 25% - 35% of net sales.This transaction, coupled with an $11 million financing led by existing investors, Rosalind Advisors and AIGH Capital Management LLC, is expected to fund Biofrontera Inc. to profitability. WOBURN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the developme
WOBURN, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), confirms a disclosure by the Management Board of Biofrontera AG on June 10, 2025, according to which the two companies are in negotiations regarding a possible combination of the two companies or an adjustment of the license and supply agreement between them. The latter could result in the transfer of certain rights and obligations from Biofrontera AG to Biofrontera Inc. and a reduction in the transfer price for Biofrontera Inc.'s licensed products sold in the US. The terms of any such agreement or agre
Biofrontera received patent approval for the revised formulation of Ameluz® in April 2025, extending patent protection through to December 2043.The Orange Book is published by the U.S. Food and Drug Administration (FDA) and lists all approved prescription drug products, along with patent and exclusivity information.Inclusion signifies FDA recognition of the revised formulation's approved status and its intellectual property protection. WOBURN, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), today announced the inclusion of the patent for its propylene glycol
8-K - Biofrontera Inc. (0001858685) (Filer)
8-K - Biofrontera Inc. (0001858685) (Filer)
8-K - Biofrontera Inc. (0001858685) (Filer)
4 - Biofrontera Inc. (0001858685) (Issuer)
4 - Biofrontera Inc. (0001858685) (Issuer)
4 - Biofrontera Inc. (0001858685) (Issuer)
Benchmark initiated coverage of Biofrontera with a rating of Buy and set a new price target of $11.00
Roth Capital initiated coverage of Biofrontera with a rating of Buy and set a new price target of $20.00
Conference call begins at 10:00 a.m. Eastern time on Friday, May 16, 2025 WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today reported financial results for the three months ended March 31, 2025 and provided a business update. Highlights from the first quarter of 2025 and subsequent weeks included the following: Total revenues for the first quarter of 2025 were $8.6 million, a 9% increase from the same period of the prior year.Cash and cash equivalents were $1.8 million as of March 31, 2025, compared with $5.9 million on December 31, 2024.Announce
Conference scheduled for Friday, March 21, 2025 at 10:00 a.m. Eastern time Woburn, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today reported financial results for the three and twelve months ended December 31, 2024. Highlights from 2024 and subsequent weeks include: Reported record total revenues of $37.3 million for 2024, reflecting a 9.5% increase from $34.1 million in 2023 with Q4 2024 growing 18.5% over Q4 2023. The growth was primarily driven by increases in Ameluz® sales volume and unit price, and the successful launch of our RhodoLED® XL Lam
WOBURN, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the development and commercialization of dermatological products, today announced that it will report financial results for the three and 12 months ended December 31, 2024 on Friday, March 21, 2025. The results will be released before the market opens on Friday, March 21 and the company will host a conference call on Friday, March 21 at 10:00am Eastern Time. Conference Call and Webcast Information DateFriday, March 21, 2025Time10:00 AM Eastern TimeDial In Numbers1-877-877-1275 (U.S.)1-412-858-5202 (international)WebcastFourth Quarter and FY 2024 Financial Results a
WOBURN, MA / ACCESSWIRE / August 29, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announced today the appointment of Samantha (Sam) Widdicombe to the newly created position of Senior Director, Strategic Accounts and Communications. Biofrontera created this position in response to the growing demand and opportunity for specialized sales and marketing approaches resulting from an evolving landscape of medical practices consolidating into larger integrated organizations.Reporting to Mark Baldyga, Vice President of Sales and Marketing, Ms. Widdicombe joins Biofrontera with over
WOBURN, MA / ACCESSWIRE / July 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the appointment of Heikki Lanckriet, Ph.D. to its Board of Directors. Dr. Lanckriet brings to Biofrontera more than 20 years of commercial and scientific experience in the life sciences industry, along with proven success in developing high-growth technology companies.Dr. Lanckriet was nominated to Biofrontera Inc.'s Board of Directors by Biofrontera AG under the terms of the April 2023 settlement agreement between the two companies previously disclosed in the Company's Current Report o
Executive Chairman Hermann Luebbert to Assume CEO Responsibilities, Reaffirms the Company's Strategic Plan and 2023 Commercial GoalsWOBURN, MA / ACCESSWIRE / May 12, 2023 / Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, announces the resignation of Erica Monaco as Chief Executive Officer, which will be effective pending the completion of a near term transition of responsibilities with the Board of Directors. Hermann Luebbert, Biofrontera's Executive Chairman and founder, will assume the CEO responsibilities. Ms. Monaco intends to pursue other professional opportunities and her resignation did not res
SC 13G/A - Biofrontera Inc. (0001858685) (Subject)
SC 13G/A - Biofrontera Inc. (0001858685) (Subject)
SC 13G/A - Biofrontera Inc. (0001858685) (Subject)